{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:42Z","timestamp":1789726242857,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jns.2022.120444","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T12:23:15Z","timestamp":1664540595000},"page":"120444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Capecitabine related neurotoxicity: Clinical and radiologic features"],"prefix":"10.1016","volume":"442","author":[{"given":"Chiew-Sern","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaslyn Linyi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Jiang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2022.120444_bb0005","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0959-8049(01)00417-8","article-title":"Future treatment options with capecitabine in solid tumours","volume":"38","author":"Wilke","year":"2002","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.jns.2022.120444_bb0025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/1078155210374891","article-title":"Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report","volume":"17","author":"Fantini","year":"2011","journal-title":"J. Oncol. Pharm. Pract. Offl. Publ. Int. Soc. Oncol. Pharm. Pract."},{"key":"10.1016\/j.jns.2022.120444_bb0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.neuro.2014.02.010","article-title":"Subacute reversible toxic encephalopathy related to treatment with capecitabine: a case report with literature review and discussion of pathophysiology","volume":"42","author":"Lyros","year":"2014","journal-title":"Neurotoxicology"},{"issue":"4","key":"10.1016\/j.jns.2022.120444_bb0010","first-page":"331","article-title":"Toxic encephalopathy induced by capecitabine","volume":"66","author":"Niemann","year":"2004","journal-title":"Oncology 2004"},{"issue":"1","key":"10.1016\/j.jns.2022.120444_bb0015","first-page":"70","article-title":"Capecitabine-induced cerebellar toxicity","volume":"6","author":"Renouf","year":"2006","journal-title":"Clin. Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.jns.2022.120444_bb0020","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.clml.2014.01.005","article-title":"Posterior reversible encephalopathy syndrome (PRES) complicating newly-diagnosed diffuse large B-cell lymphoma","volume":"14","author":"Sengupta","year":"2014","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"7","key":"10.1016\/j.jns.2022.120444_bb0035","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1177\/1078155220914704","article-title":"Posterior reversible encephalopathy syndrome: a rare neurotoxicity after capecitabine","volume":"26","author":"Monti","year":"2020","journal-title":"J. Oncol. Pharm. Pract. Offl. Publ. Int. Soc. Oncol. Pharm. Pract."},{"issue":"9","key":"10.1016\/j.jns.2022.120444_bb0040","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1212\/WNL.0000000000007012","article-title":"Teaching NeuroImages: transient mutism associated with splenium lesion in capecitabine-induced leukoencephalopathy","volume":"92","author":"Nicoletti","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2022.120444_bb0045","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1536\/ihj.54.417","article-title":"Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy","volume":"54","author":"Endo","year":"2013","journal-title":"Int. Heart J."},{"issue":"4","key":"10.1016\/j.jns.2022.120444_bb0050","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2169\/internalmedicine.0961-18","article-title":"Capecitabine-induced leukoencephalopathy","volume":"58","author":"Yoshimura","year":"2019","journal-title":"Intern. Med."},{"issue":"3","key":"10.1016\/j.jns.2022.120444_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3941\/jrcr.v10i3.2686","article-title":"Capecitabine-induced leukoencephalopathy involving the bilateral corticospinal tracts","volume":"10","author":"Tan","year":"2016","journal-title":"J. Radiol. Case Rep."},{"issue":"2","key":"10.1016\/j.jns.2022.120444_bb0060","first-page":"121","article-title":"Capecitabine-related neurotoxicity presenting as trismus","volume":"3","author":"Couch","year":"2003","journal-title":"Clin. Colorectal Cancer"},{"issue":"11","key":"10.1016\/j.jns.2022.120444_bb0065","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1212\/01.wnl.0000187313.83515.7e","article-title":"Capecitabine-induced multifocal leukoencephalopathy: a report of five cases","volume":"65","author":"Videnovic","year":"2005","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2022.120444_bb0070","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/1078155217739686","article-title":"Acute reversible toxic encephalopathy during capecitabine and oxaliplatin treatment","volume":"25","author":"Godinho","year":"2019","journal-title":"J. Oncol. Pharm. Pract. Offl. Publ. Int. Soc. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.jns.2022.120444_bb0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1078155209349201","article-title":"Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer","volume":"16","author":"Gounaris","year":"2010","journal-title":"J. Oncol. Pharm. Pract. Offl. Publ. Int. Soc. Oncol. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.jns.2022.120444_bb0080","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/CAD.0000000000000737","article-title":"Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics","volume":"30","author":"Saif","year":"2019","journal-title":"Anti-Cancer Drugs"},{"issue":"2","key":"10.1016\/j.jns.2022.120444_bb0085","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00280-005-0159-4","article-title":"5-fluorouracil can cross brain-blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma","volume":"58","author":"Formica","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.jns.2022.120444_bb0090","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1743-7563.2012.01544.x","article-title":"Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review","volume":"8","author":"Femia","year":"2012","journal-title":"Asia-Pacific J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jns.2022.120444_bb0095","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/02841860701721785","article-title":"Capecitabine-induced oromandibular dystonia: a case report and literature review","volume":"47","author":"Ngeow","year":"2008","journal-title":"Acta Oncol."},{"issue":"4","key":"10.1016\/j.jns.2022.120444_bb0100","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4103\/0973-1482.146134","article-title":"Oxaliplatin-induced posterior reversible encephalopathy syndrome with isolated involvement of pons","volume":"11","author":"Tang","year":"2015","journal-title":"J. Cancer Res. Ther."},{"issue":"566","key":"10.1016\/j.jns.2022.120444_bb0125","first-page":"75","article-title":"First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profifile compared with intravenous 5-fluorouracil\/leucovorin","volume":"13","author":"Cassidy","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jns.2022.120444_bb0130","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1212\/WNL.56.1.110","article-title":"5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency","volume":"56","author":"Franco","year":"2001","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2022.120444_bb0135","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5491\/SHAW.2012.3.4.243","article-title":"Toxic encephalopathy","volume":"3","author":"Kim","year":"2012","journal-title":"Saf. Health Work"},{"issue":"4","key":"10.1016\/j.jns.2022.120444_bb0140","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjc.6601973","article-title":"Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation","volume":"91","author":"Milano","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jns.2022.120444_bb0105","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cncr.20878","article-title":"Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma","volume":"103","author":"Chansky","year":"2005","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jns.2022.120444_bb0145","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/bjc.2013.517","article-title":"Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)","volume":"109","author":"Louie","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.jns.2022.120444_bb0150","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.1992.10.7.1171","article-title":"Influence of sex and age on fluorouracil clearance","volume":"10","author":"Milano","year":"1992","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22003069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22003069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:02:46Z","timestamp":1758384166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X22003069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":27,"alternative-id":["S0022510X22003069"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120444","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capecitabine related neurotoxicity: Clinical and radiologic features","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120444"}}